Take the risk out of your orphan drug distribution in Europe
The staggering complexity of launching drugs into a new market can mean that patients in Europe are missing out on potential life-changing treatments developed by US biotechs. Unlike in the US, where it is possible to reach patients anywhere in the country with one license, one language, and one supply chain, in Europe it is necessary to think about meeting the requirements of 27 different countries.
Download this guide to learn how to navigate the complex European landscape, including takeaways on:
- The potential challenges
- The benefits of collaborating with a European partner, such as:
- Late stage-customization
- Efficient and reliable supply chain
- Cash collection